McKesson agreed to acquire Precision Medicine Group in an all-cash deal valued at about $2.25 billion to expand oncology clinical research and commercialization services. The combination aims to connect McKesson’s distribution network with Precision’s biomarker intelligence, lab services, market access consulting, and global clinical trial execution capabilities. The deal follows the continued buildout of integrated services that help biotech firms manage the end-to-end path from molecular discovery through commercial launch, with closing subject to regulatory clearances.